STOCK TITAN
  1. Home
  2. News
  3. XBIO

Xenetic Biosciences Inc - XBIO STOCK NEWS

Welcome to our dedicated news page for Xenetic Biosciences (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xenetic Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xenetic Biosciences's position in the market.

News
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Rhea-AI Summary
Xenetic Biosciences (XBIO) reports financial results for 2023, highlighting progress in its DNase-based oncology program towards a Phase 1 clinical study for treating pancreatic carcinoma and other solid tumors. The company ended the year with $9.0 million in cash to fund operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
earnings
-
News
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Rhea-AI Summary
Xenetic Biosciences, Inc. (NASDAQ:XBIO) has entered into agreements with the University of Virginia to advance the development of its systemic DNase program targeting neutrophil extracellular traps. The company has an option to acquire an exclusive license to any new intellectual property arising from the DNase research program. The research is overseen by Dr. Allan Tsung, who is internationally recognized for leading substantial research on the role of NETs in tumor growth, metastasis, and resistance to existing cancer therapies. Xenetic is working towards its first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
none
-
News
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Xenetic Biosciences, Inc. (NASDAQ: XBIO) reported encouraging preclinical data guiding the pathway to the first in human trial for their DNase-based oncology platform. They are driving development towards a Phase 1 program for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. The company also continued partnering discussions to advance the development of systemic DNase and DNase-Armored CAR T programs, ending the quarter with $9.8 million of cash to fund operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
earnings
News
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Rhea-AI Summary
Xenetic Biosciences CEO to participate in Virtual Investor Ask the CEO Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.75%
Tags
conferences
-
News
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Xenetic Biosciences to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
conferences
-
News
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Xenetic Biosciences, Inc. (NASDAQ:XBIO) reported its financial results for the second quarter of 2023, highlighting the progress made in advancing its DNase-based oncology platform towards Phase 1 clinical development. The company executed the first Collaborator Statement of Work as part of a collaboration agreement with VolitionRx and CLS Therapeutics, along with continued participation in conferences and investor-focused events. Financially, the company reported a net loss of approximately $1.1 million for the quarter ended June 30, 2023, with a decrease in research & development expenses and an increase in royalty payments from its sublicense with Takeda Pharmaceuticals Co. Ltd. The company ended the quarter with approximately $10.7 million of cash and no debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
earnings
News
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
conferences
-
News
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
Rhea-AI Summary
Xenetic Biosciences, Inc. announces a one-for-ten reverse stock split of its common stock, effective May 15, 2023. Fractional shares will be rounded up to the nearest whole share. Stockholders do not need to send in their current stock certificates. Common stock will trade on the Nasdaq Capital Market under the symbol 'XBIO' and new CUSIP number 984015 602.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.5%
Tags
none
-
News
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.5%
Tags
earnings
News
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
Rhea-AI Summary
Xenetic Biosciences engages Dr. Reid P. Bissonnette as executive consultant for translational research and development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
management
Stock XBIO logo
Xenetic Biosciences Inc

Nasdaq:XBIO

XBIO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

XBIO Stock Data

6.67M
1.25M
19.05%
1.1%
0.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Framingham

About XBIO

xenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. xenetic is also working together with shire plc (formerly baxalta, baxter incorporated and baxter healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation factor viii. this collaboration relies on xenetic's polyxen technology to conjugate polysialic acid